Lepu Biopharma Co., Ltd.
Research Lepu Biopharma Co., Ltd. (2157.HK) on Bullrun: market cap HKD 6.35B, P/E 20.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2157.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 6.35B
- P/E20.7
- Financial periodFY2025
- RevenueCNY 934.87M
- Revenue growth154.2%
- Net incomeCNY 261.36M
- Free cash flow-CNY 131.41M
- Gross margin90.4%
Valuation Snapshot
latest market cap is HKD 6.35B; P/E is 20.7.
Peer valuation comparison
Latest P/E is 20.71x versus a Healthcare sector median of 21.69x (4.5% below).
Latest P/E is 20.71x versus a China median of 16.26x (27.3% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 934.87M | CNY 261.36M | -CNY 131.41M | 90.4% | 0.15 | CNY 853.03M | CNY 1.06B | CNY 1.39B |
| FY2024 | CNY 367.79M | -CNY 411.38M | -CNY 258.14M | 79.7% | -0.24 | CNY 401.29M | CNY 850.16M | CNY 702.83M |
| FY2023 | CNY 225.35M | -CNY 22.10M | -CNY 292.04M | 87.5% | -0.01 | CNY 426.02M | CNY 746.82M | CNY 896.91M |
| FY2022 | CNY 15.57M | -CNY 689.05M | -CNY 596.38M | 87.1% | -0.42 | CNY 669.40M | CNY 690.30M | CNY 900.76M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 6.35B | 20.7 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Lepu Biopharma Co., Ltd.
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of MSI-H/dMMR solid tumors solid tumors and melanoma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lepu Biopharma Co., Ltd.'s market cap?
Lepu Biopharma Co., Ltd.'s market capitalization is HKD 6.35B.
What is Lepu Biopharma Co., Ltd.'s P/E ratio?
Lepu Biopharma Co., Ltd.'s price-to-earnings (P/E) ratio is 20.7.
What does Lepu Biopharma Co., Ltd. do?
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of MSI-H/dMMR solid tumors solid tumors and melanoma.